DxTerity Buys Cancer Dx Rights from SourceMDx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing technology company DxTerity Diagnostics said today that it has acquired the intellectual property rights to several blood-based cancer diagnostic tests from SourceMDx.

The IP covers gene expression assays for early diagnosis of breast and lung cancer and a test for determining survival and response to therapy for melanoma patients. They are covered by a portfolio of more than 30 US and international patent filings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.